| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1033031510 |
| P356 | DOI | 10.1007/S00467-013-2479-7 |
| P698 | PubMed publication ID | 23812351 |
| P5875 | ResearchGate publication ID | 243968517 |
| P2093 | author name string | Caitlin E Carter | |
| Nadine M Benador | |||
| P2860 | cites work | Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome | Q24606843 |
| Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome | Q24622189 | ||
| Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome | Q24685473 | ||
| Clinical applications of therapeutic apheresis | Q30451700 | ||
| Frequency of immediate adverse effects associated with therapeutic apheresis | Q33144650 | ||
| Familial hemolytic uremic syndrome associated with complement factor H deficiency | Q33336276 | ||
| Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. | Q33338223 | ||
| A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders | Q33371578 | ||
| Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? | Q33372382 | ||
| Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome | Q33375728 | ||
| Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors | Q69897321 | ||
| Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group | Q70145757 | ||
| Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in children | Q70575943 | ||
| Goodpasture's syndrome in a child: natural history and effect of treatment | Q70814475 | ||
| Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background | Q33376237 | ||
| Complement and the atypical hemolytic uremic syndrome in children. | Q33380163 | ||
| Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group | Q33390678 | ||
| Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura | Q33391705 | ||
| Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome | Q33393304 | ||
| Successful therapeutic plasma exchange in a 3.2-kg body weight neonate with atypical hemolytic uremic syndrome | Q33394147 | ||
| Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome | Q33395251 | ||
| Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations | Q33396013 | ||
| Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings | Q33396908 | ||
| Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants | Q33398910 | ||
| Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics | Q33400211 | ||
| Anticoagulation techniques in apheresis: from heparin to citrate and beyond | Q33400909 | ||
| Therapeutic plasmapheresis using membrane plasma separation | Q33402168 | ||
| Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura | Q33471756 | ||
| Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. | Q33949590 | ||
| Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis | Q34122035 | ||
| Complications of apheresis in children. | Q34690604 | ||
| Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation | Q34695450 | ||
| Characteristics and outcomes of patients with Goodpasture's syndrome | Q35070400 | ||
| ABO-incompatible organ and bone marrow transplantation: current status | Q35116720 | ||
| Outcomes after renal transplantation for FSGS in children | Q35841622 | ||
| Antibody-mediated rejection in kidney transplantation: a review | Q35915453 | ||
| Blood volume studies in healthy children | Q36006334 | ||
| Circulating suPAR in two cohorts of primary FSGS. | Q36426091 | ||
| Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children | Q36691170 | ||
| Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies | Q36736625 | ||
| Treating severe Henoch-Schönlein and IgA nephritis with plasmapheresis alone | Q36832308 | ||
| Clinical features and outcome of pediatric Wegener's granulomatosis | Q36832438 | ||
| Drug removal by plasmapheresis: an evidence-based review. | Q36982684 | ||
| Technical considerations for renal replacement therapy in children | Q37268200 | ||
| Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts | Q37573649 | ||
| Advances in diagnosing and managing antibody-mediated rejection | Q37676032 | ||
| The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection | Q37992871 | ||
| Describing the effectiveness of immunosuppression drugs and apheresis in the treatment of transplant patients. | Q39653739 | ||
| Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis | Q70989780 | ||
| Apheresis and ACE inhibitors | Q72653666 | ||
| Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts | Q73111199 | ||
| Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange | Q73114911 | ||
| Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group | Q73148705 | ||
| Concurrent centrifugation plasmapheresis and continuous venovenous hemodiafiltration | Q73400198 | ||
| Effect of pre-and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children | Q73726843 | ||
| Anti-glomerular basement membrane disease | Q73931065 | ||
| Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation | Q74265391 | ||
| Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children | Q74592635 | ||
| Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial | Q78355496 | ||
| Treatment of Waldenstrom's macroglobulinemia by plasmapheresis | Q78910054 | ||
| Preventing recurrence of focal segmental glomerulosclerosis following renal transplantation: a case report | Q79346678 | ||
| Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial | Q79364646 | ||
| Successful management of anti-GBM disease in a 5 1/2-year-old girl | Q79892595 | ||
| Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant | Q79968166 | ||
| Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan | Q80198398 | ||
| Therapeutic plasma exchange performed in parallel with extra corporeal membrane oxygenation for antibody mediated rejection after heart transplantation | Q80199961 | ||
| Recurrence of nephrotic proteinuria in children with focal segmental glomerulosclerosis after renal transplantation treated with plasmapheresis and immunoadsorption: case reports | Q80223548 | ||
| Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology | Q80367574 | ||
| Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis | Q80507400 | ||
| Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis | Q80538509 | ||
| Successful deceased donor renal transplant in a sensitized pediatric recipient with the use of plasmapheresis | Q81143544 | ||
| Anti-Angiotensin Type 1 Receptor Antibodies Associated With Antibody Mediated Rejection in Donor HLA Antibody Negative Patients | Q82213207 | ||
| Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation | Q83330294 | ||
| Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation | Q83454850 | ||
| Acute antibody-mediated rejection in paediatric renal transplant recipients | Q83774038 | ||
| ABO-incompatible kidney transplantation in children | Q84575553 | ||
| Theoretical basis of pathogenic substance removal during plasmapheresis | Q85046098 | ||
| Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
| Prediction of blood volume in normal human adults. | Q41564951 | ||
| Removal kinetics of therapeutic apheresis | Q42529455 | ||
| Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation | Q43181339 | ||
| Single-center analysis of early recurrence of nephrotic syndrome following renal transplantation in children | Q43185261 | ||
| Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation | Q43231294 | ||
| Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation | Q43241188 | ||
| Comparison of citrate anticoagulation during plasma exchange with different replacement solutions | Q43288964 | ||
| ABO-incompatible living-donor kidney transplantation in children | Q43752470 | ||
| Recurrent focal glomerulosclerosis: natural history and response to therapy | Q43766653 | ||
| Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis | Q43843951 | ||
| Wegener granulomatosis in children and young adults. A case study of ten patients | Q43901886 | ||
| Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection | Q44469234 | ||
| Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients | Q44609131 | ||
| Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. | Q44627132 | ||
| Plasmapheresis therapy for rapidly progressive Henoch-Schönlein nephritis | Q44936916 | ||
| Plasma exchange conditioning for ABO-incompatible renal transplantation | Q44993186 | ||
| Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls | Q45027158 | ||
| Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience | Q45191216 | ||
| Diagnosis and treatment of acute humoral kidney allograft rejection. | Q46045914 | ||
| Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches | Q46083436 | ||
| Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience | Q46155740 | ||
| Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 | ||
| Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study | Q46494004 | ||
| ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up | Q46518667 | ||
| Management of familial hypertriglyceridemia during pregnancy with plasma exchange | Q46708642 | ||
| Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis | Q46723567 | ||
| Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients | Q46816101 | ||
| Clinical spectrum and outcome of crescentic glomerulonephritis in children in developing countries | Q46856437 | ||
| Plasma exchange using a continuous venovenous hemofiltration machine in children | Q47369314 | ||
| Vascular access complications in long-term pediatric hemodialysis patients | Q47393056 | ||
| Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant | Q47569936 | ||
| Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. | Q47862854 | ||
| ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. | Q50579449 | ||
| Blood transfusions in children: a multi-institutional analysis of practices and complications. | Q50675478 | ||
| Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 | ||
| A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. | Q53639822 | ||
| Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide. | Q54248452 | ||
| Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. | Q55050612 | ||
| Eculizumab for congenital atypical hemolytic-uremic syndrome. | Q55051403 | ||
| Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. | Q55052886 | ||
| Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children | Q58620555 | ||
| A 25-year experience with pediatric anti-glomerular basement membrane disease | Q62630706 | ||
| Crescentic glomerulonephritis in children | Q67518159 | ||
| A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group | Q68037761 | ||
| A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group | Q68102206 | ||
| Good outcome in anti-glomerular basement membrane nephritis | Q68181342 | ||
| Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters | Q68309488 | ||
| Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts | Q68544249 | ||
| The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels | Q68872851 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 35-50 | |
| P577 | publication date | 2013-06-29 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. | |
| P478 | volume | 29 |
| Q39321709 | A randomized crossover study comparing membrane and centrifugal therapeutic plasma exchange procedures |
| Q28661698 | A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS) |
| Q99372499 | Double filtration plasmapheresis - 10-year pediatric experience as an alternative to plasma exchange |
| Q87611503 | Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units |
| Q36306747 | Plasma exchange for paediatric kidney disease-indications and outcomes: a single-centre experience |
| Q38796561 | Therapeutic plasma exchange in children: one center's experience. |
Search more.